MedTrace Logo

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2026-04-23

No results posted yet for this study

Summary

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Conditions

Interventions

DRUG

Tovorafenib

Given orally

Sponsors & Collaborators

  • Sabine Mueller, MD, PhD

    lead OTHER

  • Day One Biopharmaceuticals, Inc.

    collaborator INDUSTRY

Principal Investigators

  • Sabine Mueller, MD, PhD, MAS · University of California, San Francisco

  • Cassie Kline, MD · Children's Hospital of Philadelphia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-12
Primary Completion
2027-03-01
Completion
2028-03-01
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465174 on ClinicalTrials.gov